09 August 2021 – Race Oncology Limited (“Race”) is pleased to announce that the first patient has been dosed in the Phase 1b/2 trial in relapsed/refractory Acute Myeloid Leukaemia (ASX Announcement: 22 June 2021). This investigator-led trial supervised by Professor…
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP) distribution and sales agreement in Israel with TrueMed Ltd. According to Race, TrueMed is a pharmaceutical distributor with experience in driving NPPs in Israel.…
A Perth family tells the story of their son’s battle with Acute Myeloid Leukaemia. When Kai got sick, they searched the world for answers.
Race Oncology is pleased to announce that it has received a letter from the FDA advising that Bisantrene has been granted Rare Paediatric Disease (RPD) designation for the treatment of childhood Acute Myeloid Leukaemia (AML). The RPD designation means Bisantrene has…
The poster below details the long-term survival case report of two paediatric relapsed or refractory Acute Myeloid Leukemia patients treated with Bisantrene Combination Therapy.
Race Oncology’s second Bisantrene patent has received “Notice of Allowance” in the US. Once ‘allowed’ in a jurisdiction, a patent can proceed to a ‘granted’ patent. The patent titled, “Compositions to Improve the Therapeutic Benefit of Bisantrene and Analogs and…
A key Bisantrene patent has received “Notice of Allowance” in the United States, which extends the commercial exclusivity period for the drug in the American market. The patent titled, “Combinatorial Methods to Improve the Therapeutic Benefit of Bisantrene and Analogs…
Race Oncology is pleased to announce the company has been invited to present at the ‘Biotech Showcase’ during the J.P. Morgan Healthcare Conference in San Francisco next week. Race Oncology Chief Executive Peter Molloy will present on Monday 8 January,…
